Want to join the conversation?
$LLY said that its 1Q16 non-GAAP OpEx as a percent of revenue was up slightly vs. 1Q15 due to the baricitinib milestone payments to Incyte, which totaled $55MM in the quarter. Excluding these payments, OpEx percent was flat. The company expects 2016 OpEx, which at midpoint of the ranges implies an improvement of 200-250 BP.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.